Skip to content
Visionary Ventures
Venture capital fund investing life sciences focusing in ophthalmology medical devices and pharmaceuticals.
Visionary VenturesVisionary Ventures
  • HOME
  • OPHTHALMOLOGY FUND
  • Visionary KOLs
  • TEAM
    • Investment Committee
    • Fund Management
  • PORTFOLIO
  • NEWS
  • CONTACT
  •  INVESTOR LOGIN
Fund Menu
Search
  • HOME
  • OPHTHALMOLOGY FUND
  • Visionary KOLs
  • TEAM
    • Investment Committee
    • Fund Management
  • PORTFOLIO
  • NEWS
  • CONTACT
  •  INVESTOR LOGIN

Monthly Archives: October 2019

Orasis Featured in Forbes Article

News, OrasisBy Garrett HamontreeOctober 18, 2019

Eye Drops Proven To Reverse Vision Loss In Clinical Trial

Orasis Pharmaceuticals Announces Successful Phase IIb Results

News, OrasisBy Garrett HamontreeOctober 14, 2019

Orasis Pharmaceuticals announced its CSF-1 eye drop has successfully met the primary endpoint in a phase 2b clinical study in individuals with presbyopia. CSF-1 successfully demonstrated statistically significant improvement in distance-corrected near visual acuity of a 3-line or greater gain. In addition, CSF-1 demonstrated an exceptional safety and tolerability profile. 

  • Home
  • Ophthalmology
  • Team
    • Investment Committee
    • Visionary KOLs
    • Fund Management
  • Portfolio
  • News
  • Contact
  • Investor Portal
Footer Menu

© 2019 Visionary Ventures. All Rights Reserved.

Go to Top